Muscle Relaxants and Renal Failure

  • Gwendolyn B. Graybar
Part of the Developments in Critical Care Medicine and Anesthesiology book series (DCCA, volume 14)


Of all the drugs used in anesthesia, muscle relaxants are among the most affected by renal failure. The uremic state is associated with a variety of derangements which predispose for adverse drug reactions. These include: decreased renal excretion of drugs and their metabolites, decreased renal metabolism, altered pharmacokinetics including bioavailability, volumes of distribution (V D ), changes in protein binding, lipid solubility, total body weight, altered pharmacodynamics, hepatic metabolism, and altered elimination. In addition, there may be changes in end organ response [1]. Acidosis affects the action of some drugs and is the result of metabolism of others. Antacids decrease the absorption of many drugs. Bennett et al. [2] compiled an extensive list of guidelines for the prescription of drugs in renal failure. Dosage assessments for renal failure and the effects of dialysis upon each drug are listed as well as toxicity and adverse systemic side effects. In general, the loading dose of a drug in renal failure is similar to that for a patient without end-stage renal disease (ESRD).


Muscle Relaxant Neuromuscular Blockade Plasma Cholinesterase Anephric Patient Nondepolarizing Muscle Relaxant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brater DC: Drug Use in Renal Disease. Sydney, Australia: Health Science Press, 1983, p. 4.Google Scholar
  2. 2.
    Bennett WM, Aronoff GR, Morrison G, et al.: Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 3:155, 1983.PubMedGoogle Scholar
  3. 3.
    Lundy JS. Balanced anesthesia. Minnesota Med 9:399, 1926Google Scholar
  4. 4.
    Foldes FF: Muscle Relaxants in Anesthesiology. Springfield, IL: CC Thomas, 1957.Google Scholar
  5. 5.
    Scott RPF, Goat VA: Atracurium: its speed of onset. A comparison with suxamethonium. Br J Anaesth 54:909, 1982.PubMedGoogle Scholar
  6. 6.
    Hunt R, Taveau RM: On the physiological action of certain cholin derivatives and new methods for detecting cholin. Br Med J 2:1788, 1906.Google Scholar
  7. 7.
    Harper JK: Prolonged respiratory paralysis after succinylcholine. Br Med J 1:866, 1952.Google Scholar
  8. 8.
    Hewer CL: Prolonged respiratory paralysis after succinylcholine. Br Med J 1:971, 1952.Google Scholar
  9. 9.
    Ernst EA, Smith JC: A pharmacogenetic study of a family exhibiting atypical and “silent” genes for plasma cholinesterase. Anesthesiology 28:1085, 1967.PubMedGoogle Scholar
  10. 10.
    McArdle B: The serum cholinesterase in jaundice and diseases of the liver. Quart J Med 33:107, 1940.Google Scholar
  11. 11.
    Foldes FF, Swerdlow M, Lipschitz E, et al.: Comparison of the respiratory effects of suxamethonium and suxethonium in man. Anesthesiology 17:559, 1956.PubMedGoogle Scholar
  12. 12.
    Wyant GM: The anaesthetist looks at tissue transplantation: three years’ experience with kidney transplants. Can Anaesth Soc J 14:255, 1967.PubMedGoogle Scholar
  13. 13.
    Virtue RW: Hazards and safeguards in the use of chlorpromazine and other relaxing agents in anesthesia. Surg Clin N Amer (October) 1439, 1957.Google Scholar
  14. 14.
    Holmes JH, Nakamoto S, Sawyer KC, et al.: Changes in blood composition before and after dialysis with the Kolff twin coil kidney. Trans Am Soc Artif Intern Organs 4:16, 1958.Google Scholar
  15. 15.
    Desmond JW, Gordon RA: The effect of haemodialysis on blood volume and plasma cholinesterase levels. Can Anaesth Soc J 16:292, 1969.PubMedGoogle Scholar
  16. 16.
    Thomas JL, Holmes JH: Effect of hemodialysis on plasma cholinesterase. Anesth Analg 49:323, 1970.PubMedGoogle Scholar
  17. 17.
    Simon NM, deGreco F, Dietz AA, et al.: Serum cholinesterase deficiency in renal failure. Trans Am Soc Artif Int Organs 15:328, 1969.Google Scholar
  18. 18.
    Weintraub H, Heisterkamp DV, Cooperman LH: Changes in plasma potassium concentration after depolarizing blockers in anaesthetized man. Br J Anaesth 41:1048, 1969.PubMedGoogle Scholar
  19. 19.
    Evers WE, Racz GB, Dobkin AB: A study of plasma potassium and electrocardiographic changes after a single dose of succinylcholine. Can Anaesth Soc J 16:273, 1969.PubMedGoogle Scholar
  20. 20.
    List WF: Serum potassium changes during induction of anaesthesia. Br J Anaesth 39:480, 1967.PubMedGoogle Scholar
  21. 21.
    Miller RD, Way WL, Hamilton WK, et al.: Succinylcholine-induced hyperkalemia in patients with renal failure? Anesthesiology 36:138, 1972.PubMedGoogle Scholar
  22. 22.
    Koide M, Waud BE: Serum potassium concentrations after succinylcholine in patients with renal failure. Anesthesiology 36:142, 1972.PubMedGoogle Scholar
  23. 23.
    Stoelting RK, Peterson C: Adverse effects of increased succinylcholine dose following d-tubocurarine pretreatment. Anesth Analg 54:282, 1975.PubMedGoogle Scholar
  24. 24.
    Tolmie JD, Joyce TH, Mitchell GD: Succinylcholine danger in the burned patient. Anesthesiology 28:467, 1967.PubMedGoogle Scholar
  25. 25.
    Lowenstein E: Succinylcholine administration in the burned patient. Anesthesiology 27:494, 1966.Google Scholar
  26. 26.
    Kopriva C, Ratlif, Fletcher JR, et al.: Serum potassium changes after succinylcholine in patients with acute massive muscle trauma. Anesthesiology 34:246, 1971.PubMedGoogle Scholar
  27. 27.
    Mazze RI, Escue HM, Houston JB: Hyperkalemia and cardiovascular collapse following administration of succinylcholine to the traumatized patient. Anesthesiology 31:540, 1969.PubMedGoogle Scholar
  28. 28.
    Greenspan K, Wuinsch CM, Fisch C: Relationship between potassium and vagal action on artrioventricular transmission. Circ Res 17:39, 1965.PubMedGoogle Scholar
  29. 29.
    Cooperman LH: Succinylcholine-induced hyperkalemia in neuromuscular disease. JAMA 213:1867, 1970.PubMedGoogle Scholar
  30. 30.
    Gronert GA, Theye RA: Pathophysiology of hyperkalaemia induced by succinylcholine. Anesthesiology 43:89, 1975.PubMedGoogle Scholar
  31. 31.
    Stone WA, Beach TP, Hamelberg W: Succinylcholine-danger in the spinal cord-injured patient. Anesthesiology 32:168, 1970.PubMedGoogle Scholar
  32. 32.
    Roth F, Wüthrich H: The clinical importance of hyperkalaemia following suxamethonium administration. Br J Anaesth 41:311, 1969.PubMedGoogle Scholar
  33. 33.
    Kohlschutter B, Baur H, Roth F: Suxamethonium-induced hyperkalemia in patients with severe intra-abdominal infections. Br J Anaesth 48:557, 1956.Google Scholar
  34. 34.
    Powell JN: Suxamethonium-induced hyperkalaemia in an uraemic patient. Br J Anaesth 42:806, 1970.Google Scholar
  35. 35.
    Fergusson RJ, Wright DJ, Willey RF, et al.: Suxamethonium is dangerous in polyneuropathy. Br Med J 282:298, 1981.Google Scholar
  36. 36.
    Walton JD, Farman JV: Suxamethonium hyperkalaemia in uraemic neuropathy. Anaesthesia 28:666, 1973.PubMedGoogle Scholar
  37. 37.
    Kuruvila KC, Schrier RW: Chronic renal failure. In: The Kidney in Anesthesia, Vol. 22, edited by Priebe HJ. (Int Anesthesiol Clinics), Boston: Little Brown, 1984, p. 101.Google Scholar
  38. 38.
    Shantharam VV: Role of the nephrologist in kidney transplantation. In: Renal Transplantation: A Multidisciplinary Approach, edited by Chatterjee SN. New York: Raven Press, 1980, p. 89.Google Scholar
  39. 39.
    Jebsen RH, Tenckhoff H, Honet JC: Natural history of uremic polyneuropathy and effects of dialysis. N Engl J 277:327, 1967.Google Scholar
  40. 40.
    Ibrahim MM, Crosland JM, Honigsberger L, et al.: Effect of renal transplantation on uraemic neuropathy. Lancet 2:739, 1974.PubMedGoogle Scholar
  41. 41.
    Brown MJ, Asbury AK: Diabetic neuropathy. Ann Neurol 15:2, 1984.PubMedGoogle Scholar
  42. 42.
    Katz J, Kountz SL, Cohn R: Anesthetic considerations for renal transplant. Anesth Analg 46:609, 1967.PubMedGoogle Scholar
  43. 43.
    Ramsey FM, Lebowitz PW, Savares J, et al.: Clinical characteristics of long term succinylcholine neuromuscular blockade during balanced anesthesia. Anesth Analg 59:110, 1980.PubMedGoogle Scholar
  44. 44.
    Foldes FF: Factors which alter the effects of muscle relaxants. Anesthesiology 20:464, 1959.PubMedGoogle Scholar
  45. 45.
    Bishop MJ, Hornbein TF: Prolonged effect of succinylcholine after neostigmine and pyridostigmine administration in patients with renal failure. Anesthesiology 58:384, 1983.PubMedGoogle Scholar
  46. 46.
    Schoenstadt DA, Whitcher CE: Observations on the mechanism of succinylcholine-induced cardiac arrhythmias. Anesthesiology 24:358, 1963.PubMedGoogle Scholar
  47. 47.
    Baraka A: Self-taming of succinylcholine-induced fasciculations. Anesthesiology 46:292, 1977.PubMedGoogle Scholar
  48. 48.
    Karhumen U, Heinonen J, Tammisto T: The effect of tubocurarine and alcuronium on suxamethonium-induced changes in cardiac rate and rhythm. Acta Anaesthesiol Scand 16:3, 1972.Google Scholar
  49. 49.
    Mathias JA, Evans-Prosser CDG, Churchill-Davidson HC: The role of the nondepolarizing drugs in the prevention of suxamethonium bradycardia. Br J Anaesth 42:609, 1970.PubMedGoogle Scholar
  50. 50.
    Tucker WK, Munson ES: Effects of succinylcholine and d-tubocurarine on epinephrine induced arrhythmias during halothane anesthesia in dogs. Anesthesiology 42:41, 1975.PubMedGoogle Scholar
  51. 51.
    Sharma PL, Narang RS: Effect of succinylcholine, gallamine, and d-tubocurarine on adrenaline-evoked ventricular arrhythmias in dogs under halothane-nitrous oxide anaesthesia. Indian J Med Res 56:1272, 1968.PubMedGoogle Scholar
  52. 52.
    Forbes MA, Dally FG: Acute hypertension during induction of anaesthesia and endotracheal intubation in normotensive man. Br J Anaesth 42:618, 1970.PubMedGoogle Scholar
  53. 53.
    Nigrovic V: Succinylcholine, cholinoceptors and catecholamines: proposed mechanism of early adverse haemodynamic reactions. Can Anaesth Soc J 31:382, 1984.PubMedGoogle Scholar
  54. 54.
    Nigrovic V, Mullough LS, Wajskol A, et al.: Succinylcholine-induced increases in plasma catecholamine levels in humans. Anesth Analg 62:627, 1983.PubMedGoogle Scholar
  55. 55.
    Condouris GA, Kopia GA: Cardiac arrhythmias induced by guanethidine in cats anesthetized with halothane. Eur J Pharmacol 68:257, 1980.PubMedGoogle Scholar
  56. 56.
    Cruickshank JM, Neil-Dwyer G, Stott AW: Possible role of catecholamines, corticosteroids, and potassium in production of electrographic abnormalities associated with subarachnoid haemorrhage. Br Heart J 36:697, 1974.PubMedGoogle Scholar
  57. 57.
    Evans RH, Smith JW: The effect of catecholamines on the influx of calcium and the development of tension in denervated mouse diaphragm muscle. Br J Pharmacol 58:109, 1976.PubMedGoogle Scholar
  58. 58.
    Rouse JN, Galley RLA, Bevan DR: Prolonged curarization following renal transplantation. Anesthesia 32:247, 1977.Google Scholar
  59. 59.
    Geha DG, Blitt CD, Moon BJ: Prolonged neuromuscular blockade with pancuronium in the presence of renal failure: a case report. Anesth Analg 55:343, 1976.PubMedGoogle Scholar
  60. 60.
    Miller RD, Matteo RS, Benet RZ, et al.: The pharmacokinetics of d-tubocurarine in man with and without renal failure. J Pharmacol Exp Ther 202:1, 1977.PubMedGoogle Scholar
  61. 61.
    Gibaldi M, Levy G, Hayton WL: Tubocurarine and renal failure. Br J Anaesth 44:163, 1972.PubMedGoogle Scholar
  62. 62.
    Churchill-Davidson HC, Way WL, de Jong RH: The muscle relaxants and renal excretion. Anesthesiology 28:540, 1967.PubMedGoogle Scholar
  63. 63.
    Riordon DD, Gilbertson AA: Prolonged curarization in a patient with renal failure. Br J Anaesth 43:506, 1971.Google Scholar
  64. 64.
    Miller RD, Stevens WC, Way WL: The effect of renal failure and hyperkalemia on the duration of pancuronium neuromuscular blockade in man. Anesth Analg 52:661, 1973.PubMedGoogle Scholar
  65. 65.
    Waser PG: Localization of 14C-pancuronium by histo- and whole body-autoradiography in normal and pregnant mice. Naunyn-Schmiedebergs Arch Pharmacol 279:399, 1973.PubMedGoogle Scholar
  66. 66.
    Thomson IR, Putnins CL: Adverse effects of pancuronium during high-dose fentanyl anesthesia for coronary artery bypass grafting. Anesthesiology 62:708, 1985.PubMedGoogle Scholar
  67. 67.
    Nana A, Cardan E, Domokos M: Blood catecholamine changes after pancuronium. Acta Anaesth Scand 17:83, 1973.PubMedGoogle Scholar
  68. 68.
    Pinaud MLJ, Souron RJ: Beta-adrenergic effect of pancuronium bromide: fact or fallacy. Anesthesiology 60:512, 1984.PubMedGoogle Scholar
  69. 69.
    Savage DS, Sleigh T, Carlyle I: The emergence of Org NC 45, l-(2β 3α, 5α, 16β, 17β)-3, 17-bis(acetyloxy)-2-l-piperidinyl)-androstan-16-YL 1-methylpiperidinium bromide, from the pancuronium series. Br J Anaesth 52:3S, 1980.Google Scholar
  70. 70.
    Savarese JJ, Kitz RJ: Does clinical anesthesia need new neuromuscular blocking agents? Anesthesiology 42:236, 1975.PubMedGoogle Scholar
  71. 71.
    Agoston S, Salt P, Newton D, et al.: The neuromuscular blocking action of Org NC 45, a new pancuronium derivative in anaesthetized patients. Br J Anaesth 52:53S, 1980.Google Scholar
  72. 72.
    Funk, DI, Crul JE, van der Pol FM: Effects of changes in acid base balance on neuromuscular blockade produced by Org NC 45. Acta Anaesthesiol Scand 24:119, 1980.PubMedGoogle Scholar
  73. 73.
    Gencarelli PJ, Swen J, Koot HW, et al.: The effects of hypercarbia and hypocarbia on pancuronium and vecuronium neuromuscular blockade in anesthetized humans. Anesthesiology 59:376, 1983.PubMedGoogle Scholar
  74. 74.
    Foldes FF, Bencini A, Newton D: Influence of halothane and enflurane on the neuromuscular blocking effects of Org NC in man. Br J Anaesth 52:64S, 1980.Google Scholar
  75. 75.
    Rupp SM, Miller RD, Gencarelli PJ: Vecuronium induced neuromuscular blockade during enflurane, isoflurane, and halothane anesthesia in humans. Anesthesiology 60:102, 1984.PubMedGoogle Scholar
  76. 76.
    Kreig N, Rutte MJ, Crul JF, et al.: Preliminary review of the interaction of Org NC 45 with anaesthetics and antibiotics in animals. Br J Anaesth 52:33S, 1980.Google Scholar
  77. 77.
    Krieg N, Hendrickx HHL, Crul JF: Influence of suxamethonium on the potency of Org NC 45 in anaesthetized patients. Br J Anaesth 53:259, 1981.PubMedGoogle Scholar
  78. 78.
    d’Hollander AA, Agoston S, Dille A, et al.: Clinical and pharmacological actions of a bolus injection of suxamethonium: two phenomena of distinct duration. B Anaesth 55:131, 1983.Google Scholar
  79. 79.
    d’Hollander A, Agoston S, Barvais L, et al.: Evolution of vecuronium requirements for stable mechanical effect: comparison with or without previous succinylcholine administration. Anesth Analg 64:319, 1985.PubMedGoogle Scholar
  80. 80.
    Fisher DM, Miller RD: Interaction of succinylcholine and vecuronium during N20 halothane anesthesia. Anesthesiology 59:A278, 1983.Google Scholar
  81. 81.
    Upton RH, Nguyen TL, Miller RD, et al.: Renal and biliary elimination of vecuronium (Org NC 45) and pancuronium in rats. Anesth Analg 61:313, 1982.PubMedGoogle Scholar
  82. 82.
    Cronnelly R, Fisher DM, Miller RD, et al.: Pharmacokinetics and pharmacodynamics of vecuronium (Org NC 45) and pancuronium in anesthetized humans. Anesthesiology 58:405, 1983.PubMedGoogle Scholar
  83. 83.
    d’Hollander A, Massaux F, Nevelsteen M, et al.: Age-dependent dose response relationship of Org NC 45 in anaesthetized patients. B Anaesth 54:653, 1982.Google Scholar
  84. 84.
    Rupp SM, Fisher DM, Miller RD, et al.: Pharmacokinetics and pharmacodynamics of vecuronium in the elderly. Anesthesiology 59:A270, 1983.Google Scholar
  85. 85.
    Calloway NO, Merrill RS: The aging of adult liver. I. Bromsulphalein and bilirubin clearances. J Am Geriatr Soc 13:594, 1965.PubMedGoogle Scholar
  86. 86.
    Salmenpera M, Peltola K, Takkunen O, et al.: Cardiovascular effects of pancuronium and vecuronium during high dose fentanyl anesthesia. Anesth Analg 62:1059, 1983.PubMedGoogle Scholar
  87. 87.
    Duvaldestin P, Berger JL, Videcoq M, et al.: Pharmacokinetics and pharmacodynamics of Org NC 45 in patients with cirrhosis. Anesthesiology 57:A238, 1982.Google Scholar
  88. 88.
    Duvaldestin P, Henzel D: Binding of tubocurarine, fazadinium, pancuronium and Org NC 45 to serum proteins in normal man and in patients with cirrhosis. B Anaesth 54:513, 1982.Google Scholar
  89. 89.
    Fahey MR, Morris RB, Miller RD, et al.: Pharmacokinetics of Org NC 45 (Norcuron) in patients with and without renal failure. B Anaesth 53:1049, 1981.Google Scholar
  90. 90.
    Meistelman C, Lienhart A, Leveque C, et al.: Pharmacology of vecuronium in patients with end stage renal failure. Anesthesiology 59:A293, 1983.Google Scholar
  91. 91.
    McLeod K, Watson MJ, Rawlins MD: Pharmacokinetics of pancuronium in patients with normal and impaired renal function. B Anaesth 48:341, 1976.Google Scholar
  92. 92.
    Bevan DR, Donati F, Gyasi H, et al.: Vecuronium in renal failure. Can Anaesth Soc J 31:491, 1984.PubMedGoogle Scholar
  93. 93.
    Hofmann AW: Beiträge zur Kenntniss der fluchtigen basen. Ann Chem 78:253, 1851.Google Scholar
  94. 94.
    Stenla JB, Waigh RD, Urwi J et al.: Atracurium: conception and inception. B Anaesth 55:35, 1983.Google Scholar
  95. 95.
    Merrett RA, Thompson CW, Webb FW: In vitro degradation of atracurium in human plasma. B Anaesth 55:61, 1983.Google Scholar
  96. 96.
    Nigrovic V, Auen M, Wajskol A: Enzymatic hydrolysis of atracurium in vivo. Anesthesiology 62:606, 1985.PubMedGoogle Scholar
  97. 97.
    Krisch K: Carboxylic ester hydrolases. In: The Enzymes, edited by Boyer PD. New York: Academic Press, 1971, p. 43.Google Scholar
  98. 98.
    Fahey MR, Rupp SM, Fisher DM, et al.: The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61:699, 1984.PubMedGoogle Scholar
  99. 99.
    Hunter JM, Jones RS, Utting JE: Use of atracurium in patients with no renal function. B Anaesth 54:1251, 1982.Google Scholar
  100. 100.
    de Bros FM, Lai A, Scott R, et al.: Pharmacokinetics and pharmacodynamics of atracurium under isoflurane anesthesia in normal and anephric patients. Anesth Analg 64:207, 1985.Google Scholar
  101. 101.
    Ward S, Neill EAM: Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). Br J Anaesth 55:1169, 1983.PubMedGoogle Scholar
  102. 102.
    d’Hollander AA, Luyckx C, Barvais L, et al.: Clinical evaluation of atracurium besylate requirement for a stable muscle relaxation during surgery: lack of age-related effects. Anesthesiology 59:237, 1983.PubMedGoogle Scholar
  103. 103.
    Ali HH, Savarese JJ, Basta SJ, et al.: Evaluation of cumulative properties of three new nondepolarizing neuromuscular blocking drugs BW A444U, atracurium and vecuronium. B Anesth 55:107S, 1983.Google Scholar
  104. 104.
    Sokoll MD, Gergis SD, Mehta M, et al.: Haemodynamic effects of atracurium in surgical patients under nitrous oxide, oxygen and isoflurane anaesthesia. B Anaesth 55:77S, 1973.Google Scholar
  105. 105.
    Philbin DM, Mackey VR, Tonuctek RC, et al.: Haemodynamic effects of bolus injections of atracurium in patients with coronary artery disease. Br J Anaesth 55:1315, 1983.Google Scholar
  106. 106.
    Pohar H, Brondt L: Haemodynamic effects of atracurium in patients after cardiac surgery. Br J Anaesth 55:139S, 1983.Google Scholar
  107. 107.
    Miller RD, Rupp SM, Fisher DM, et al.: Clinical pharmacology of vecuronium and atracurium. Anesthesiology 61:444, 1984.PubMedGoogle Scholar
  108. 108.
    Hughes R, Chapple DJ: The pharmacology of atracurium: a new competitive neuromuscular blocking agent. Br J Anaesth 53:31, 1981.PubMedGoogle Scholar
  109. 109.
    Fisher DM, Canfell C, Miller RD: Stability of atracurium administered by infusion. Anesthesiology 61:347, 1984.PubMedGoogle Scholar
  110. 110.
    Babel A: Etude comparative de la laudanosine et de la papaverine au point de vue pharma- codynamique. Rev Med Suisse Romande 19:657, 1899.Google Scholar
  111. 111.
    Mercier J, Mericer E: Action de qualques alcoloides secondaires de l’opium sur l’electrocortio gramme du chien. CR Soc Biol (Paris) 149:760, 1955.Google Scholar
  112. 112.
    Hennis PJ, Fahey MR, Miller RD, et al.: Pharmacology of laudanosine in dogs. Anesthesiology 61:A305, 1984.Google Scholar
  113. 113.
    Shi WZ, Fahey MR, Fisher DM, et al.: Laudanosine (a metabolite of atracurium) increases the minimum alveolar concentration of halothane in rabbits. Anesthesiology 63:584, 1985.PubMedGoogle Scholar
  114. 114.
    Sharma M, Fahey MR, Castagnole R, et al.: In vitro metabolic studies of atracurium with rabbit liver preparation. Anesthesiology 61:A304, 1984.Google Scholar
  115. 115.
    Ingram MD, Sclabassi RJ, Stiller RL, et al.: Cardiovascular effects and electroencephographic effects of laudanosine in “nephrectromized” cats. Anesth Analg 64:232, 1985.Google Scholar
  116. 116.
    Lanier WL, Milde.JH, Michenfelder JD: The cerebral effects of pancuronium and atracurium in halothane-anesthetized dogs. Anesthesiology 63:589, 1985.PubMedGoogle Scholar
  117. 117.
    Paton WDM, Waud DR: The margin of safety of neuromuscular transmission. J Physiol 191: 59, 1967.PubMedGoogle Scholar
  118. 118.
    Gergis SD, Sokoll MD, Mehta M, et al.: Intubation conditions after atracurium and suxamethonium. Br J Anaesth 55:83S, 1983.Google Scholar
  119. 119.
    Nagashima H, Nguyen HD, Lee S, et al.: Facilitation of rapid endotracheal intubation with atracurium. Anesthesiology 61:A289, 1984.Google Scholar
  120. 120.
    Foldes FF, Schwarz S, Ilias W, et al.: Rapid tracheal intubation with vecuronium: the priming principle. Anesthesiology 61: A289, 1984.Google Scholar
  121. 121.
    Mehta MP, Choi WN, Gergis SD, et al.: Facilitation of rapid endotracheal intubations with divided doses of nondepolarizing neuromuscular blocking drugs. Anesthesiology 62:392 1985.PubMedGoogle Scholar
  122. 122.
    Bevan JC, Doherty WG, Breen PJ, et al.: Accelerated onset of pancuronium neuromuscular block with divided doses in infants and children. Anesthesiology 61:A312, 1984.Google Scholar
  123. 123.
    Miller RD, Savarese JJ: Pharmacology of muscle relaxants, their antagonists and monitoring of neuromuscular function in anesthesia. In Anesthesia, edited by Miller RD. New York: Churchill Livingstone, 1981, p. 517.Google Scholar
  124. 124.
    Samuel JR, Powell D: Renal transplantation. Anaesthetic experience of 100 cases. Anaesthesia 25:165, 1970.PubMedGoogle Scholar
  125. 125.
    Rupp, SM, McChristian JW, Miller RD: Neostigmine antagonizes a profound neuromuscular blockade more rapidly than edrophonium. Anesthesiology 61:A297, 1984.Google Scholar
  126. 126.
    Lavery GG, Mirakhur RK, Gibson FM: A comparison of edrophonium and neostigmine for the antagonism of atracurium-induced neuromuscular block. Anesth Analg 64:867, 1985.PubMedGoogle Scholar
  127. 127.
    Payne JP, Hughes R, Azawi SA: Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 52:69, 1980.PubMedGoogle Scholar
  128. 128.
    Cronnelly R, Morris BB: Antagonism of neuromuscular blockade. Br J Anaesth 54:183, 1982.PubMedGoogle Scholar
  129. 129.
    Bradley JP, Marsland AR, O’Conner JP: Prolonged neuromuscular blockade after renal transplantation. Anaesth Intens Care 13:196, 1985.Google Scholar
  130. 130.
    Bikhazi GB, Leung I, Foldes FF: Ca-channel blockers increase potency of neuromuscular blocking agents in vivo. Anesthesiology 59. A269, 1983.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1987

Authors and Affiliations

  • Gwendolyn B. Graybar

There are no affiliations available

Personalised recommendations